Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
Published in: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 1/2016

Open Access 01-12-2016 | Study protocol

Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial

Authors: Andreas Sandø, Martin Schultz, Jesper Eugen-Olsen, Lars Simon Rasmussen, Lars Køber, Erik Kjøller, Birgitte Nybo Jensen, Lisbet Ravn, Theis Lange, Kasper Iversen

Published in: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine | Issue 1/2016

Login to get access

Abstract

Background

Several biomarkers have shown to carry prognostic value beyond current triage algorithms and may aid in initial risk stratification of patients in the emergency department (ED). It has yet to be established if information provided by biomarkers can be used to prevent serious complications or deaths. Our aim is to determine whether measurement of the blood level of the biomarker soluble urokinase plasminogen activator receptor (suPAR) can enhance early risk stratification leading to reduced mortality, lower rate of complications, and improved patient flow in acutely admitted adult patients at the ED. The main hypothesis is that the availability of suPAR can reduce all-cause mortality, assessed at least 10 months after admission, by drawing attention towards patients with an unrecognized high risk, leading to improved diagnostics and treatment.

Methods

The study is designed as a cross-over cluster randomized interventional trial. SuPAR is measured within 2 h after admission and immediately reported to the treating physicians in the ED. All ED physicians are educated in the prognostic capabilities of suPAR prior to the inclusion period. The inclusion period began January 11th 2016 and ends June 6th 2016. The study aims to include 10.000 patients in both the interventional and control arm. The results will be presented in 2017.

Discussion

The present article aims to describe the design and rationale of the TRIAGE III study that will investigate whether the availability of prognostic information can improve outcome in acutely admitted patients. This might have an impact on health care organization and decision-making.

Trial registration

The trial is registered at clinicaltrials.gov (ID NCT02643459, November 13, 2015) and at the Danish Data Protection agency (ID HGH-2015-042 I-Suite no. 04087).
Literature
1.
Farrohknia N, Castren M, Ehrenberg A, et al. Emergency department triage scales and their components: a systematic review of the scientific evidence. Scand J Trauma Resusc Emerg Med. 2011;19:42.CrossRefPubMedPubMedCentral
2.
Iversen AK, Kristensen M, Ostervig R, Forberg JL, Schou M, Iversen K. No evidence that formalized triage is superior to informally structured triage. Ugeskr Laeger. 2016;184(4):358–61.
3.
4.
Fromm R, Meyer D, Zimmerman J, et al. A double-blind, multicentered study comparing the accuracy of diagnostic markers to predict short- and long-term clinical events and their utility in patients presenting with chest pain. Clin Cardiol. 2001;24(7):516–20.CrossRefPubMed
5.
Meyer B, Huelsmann M, Wexberg P, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med. 2007;35(10):2268–73.CrossRefPubMed
6.
Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2011;58(10):1057–67.CrossRefPubMed
7.
Schuetz P, Hausfater P, Amin D, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Crit Care. 2015;19:377.CrossRefPubMedPubMedCentral
8.
Seymour CW, Cooke CR, Wang Z, et al. Improving risk classification of critical illness with biomarkers: a simulation study. J Crit Care. 2013;28(5):541–8.CrossRefPubMedPubMedCentral
9.
Stahli BE, Yonekawa K, Altwegg LA, et al. Clinical criteria replenish high-sensitive troponin and inflammatory markers in the stratification of patients with suspected acute coronary syndrome. PLoS One. 2014;9(6):e98626.CrossRefPubMedPubMedCentral
10.
Hillis GS, Zhao N, Taggart P, Dalsey WC, Mangione A. Utility of cardiac troponin I, creatine kinase-MB(mass), myosin light chain 1, and myoglobin in the early in-hospital triage of “high risk” patients with chest pain. Heart. 1999;82(5):614–20.CrossRefPubMedPubMedCentral
11.
Eapen DJ, Manocha P, Ghasemzadeh N, et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc. 2014;3(5):e001118.CrossRefPubMedPubMedCentral
12.
Haupt TH, Petersen J, Ellekilde G, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care. 2012;16(4):R130.CrossRefPubMedPubMedCentral
13.
Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268(3):296–308.CrossRefPubMed
14.
Lyngbaek S, Marott JL, Sehestedt T, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167(6):2904–11.CrossRefPubMed
15.
Raggam RB, Wagner J, Pruller F, et al. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. J Intern Med. 2014;276(6):651–8.CrossRefPubMed
16.
Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibanez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013;39(11):1945–52.CrossRefPubMed
17.
Donadello K, Scolletta S, Taccone FS, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care. 2014;29(1):144–9.CrossRefPubMed
18.
Nayak RK, Allingstrup M, Phanareth K, Kofoed-Enevoldsen A. suPAR as a biomarker for risk of readmission and mortality in the acute medical setting. Dan Med J. 2015;62(10):A5146.PubMed
19.
Østervig RM, Køber L, Forberg JL, Rasmussen LS, Eugen-Olsen J, Iversen K. SuPAR - A future prognostic biomarker in emergency medicine. Scand J Trauma Resusc Emerg Med. 2015;23 Suppl 1:A31.CrossRefPubMedCentral
20.
21.
22.
23.
Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. Int J Cardiol. 2015;184:631–6.CrossRefPubMed
24.
Sorensen MH, Gerke O, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis. 2014;237(1):60–6.CrossRefPubMed
25.
Sehestedt T, Lyngbaek S, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis. 2011;216(1):237–43.CrossRefPubMed
26.
Plesner LL, Iversen AK, Langkjaer S, et al. The formation and design of the TRIAGE study--baseline data on 6005 consecutive patients admitted to hospital from the emergency department. Scand J Trauma Resusc Emerg Med. 2015;23:106.CrossRefPubMedPubMedCentral
27.
Borne Y, Persson M, Melander O, Smith JG, Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail. 2014;16(4):377–83.CrossRefPubMed
28.
Lyngbaek S, Andersson C, Marott JL, et al. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. Clin Chem. 2013;59(11):1621–9.CrossRefPubMed
29.
Lyngbaek S, Marott JL, Moller DV, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol. 2012;110(12):1756–63.CrossRefPubMed
30.
Persson M, Ostling G, Smith G, et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke. 2014;45(1):18–23.CrossRefPubMed
31.
Gumus A, Altintas N, Cinarka H, et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:357–65.PubMedPubMedCentral
32.
Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011;30(11):1417–24.CrossRefPubMed
33.
Reichsoellner M, Raggam RB, Wagner J, Krause R, Hoenigl M. Clinical evaluation of multiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome. J Clin Microbiol. 2014;52(11):4063–6.CrossRefPubMedPubMedCentral
34.
Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2012;32(3):500–9.PubMed
35.
Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2012;222(1):8–14.CrossRefPubMed
36.
Edsfeldt A, Nitulescu M, Grufman H, et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke. 2012;43(12):3305–12.CrossRefPubMed
37.
Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010;584(9):1923–30.CrossRefPubMed
38.
Lyngbaek S, Sehestedt T, Marott JL, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2013;167(3):781–5.CrossRefPubMed
39.
40.
Carter EJ, Pouch SM, Larson EL. The relationship between emergency department crowding and patient outcomes: a systematic review. J Nurs Scholarsh. 2014;46(2):106–15.CrossRefPubMed
41.
Trentino KM, Swain SG, Burrows SA, Sprivulis PC, Daly FF. Measuring the incidence of hospital-acquired complications and their effect on length of stay using CHADx. Med J Aust. 2013;199(8):543–7.CrossRefPubMed
42.
Madsen F, Ladelund S, Linneberg A. High levels of bed occupancy associated with increased inpatient and thirty-day hospital mortality in Denmark. Health Aff (Millwood). 2014;33(7):1236–44.CrossRef
43.
44.
Thomas EJ, Studdert DM, Burstin HR, et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care. 2000;38(3):261–71.CrossRefPubMed
45.
Basse L, Thorbol JE, Lossl K, Kehlet H. Colonic surgery with accelerated rehabilitation or conventional care. Dis Colon Rectum. 2004;47(3):271–7. discussion 277–278.CrossRefPubMed
46.
Shewale JB, Correa AM, Baker CM, et al. Impact of a Fast-track Esophagectomy Protocol on Esophageal Cancer Patient Outcomes and Hospital Charges. Ann Surg. 2015;261(6):1114–23.CrossRefPubMedPubMedCentral
47.
O’Cathain A, Knowles E, Turner J, Hirst E, Goodacre S, Nicholl J. Variation in avoidable emergency admissions: multiple case studies of emergency and urgent care systems. J Health Serv Res Policy. 2016;21(1):5–14.CrossRefPubMed
Metadata
Title
Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial
Authors
Andreas Sandø
Martin Schultz
Jesper Eugen-Olsen
Lars Simon Rasmussen
Lars Køber
Erik Kjøller
Birgitte Nybo Jensen
Lisbet Ravn
Theis Lange
Kasper Iversen
Publication date
01-12-2016
Publisher
BioMed Central
DOI
https://doi.org/10.1186/s13049-016-0290-8

Other articles of this Issue 1/2016

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 1/2016 Go to the issue

Commentary

Are ethical norms and current policies still relevant in face of the recent mass terror events?

Original research

Complications after surgical management of distal lower leg fractures

Commentary

Point-of-care coagulometry in prehospital emergency patients – are international normalized ratios useful?

Original research

Myocardial function at the early phase of traumatic brain injury: a prospective controlled study

Original research

Increasing incidence of hypotension in the emergency department; a 12 year population-based cohort study

Study protocol

The ReCaPTa study - a prospective out of hospital cardiac arrest registry including multiple sources of surveillance for the study of sudden cardiac death in the Mediterranean area